Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-BOOSTER study of AKS-452X COVID-19 booster vaccination
2021-005509-28Phase 2Completed
- Sponsor
- Akston Biosciences Corporation
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of AKS-452 in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by Akston Biosciences Corporation. Primary endpoint: Immunogenicity response rate at day 28. Started Feb 2022; status: completed.
02
Drugs
AKS-452
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-005509-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005509-28.